Status: Recruiting
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.
Participants needed: 40
Trial details
Phase: Phase 4Age: 50+Biological sex: AllType: InterventionalSponsor: Hospital Authority, Hong KongUpdated: Oct 1, 2025Locations: 1
Eligibility criteria
eyes that received any anti-VEGF therapy in the prior six months, [+2]